Adverse Reactions of the Second Dose of the BNT162b2 mRNA COVID-19 Vaccine in Healthcare Workers in Korea.
Adverse Reactions of the Second Dose of the BNT162b2 mRNA COVID-19 Vaccine in Healthcare Workers in Korea.
复制标题
DOI：
10.3346/jkms.2021.36.e153
复制
发表时间：
2021-05-31
影响因子：
4.5
通讯作者：
Bae S
中科院分区：
文献类型：
--
作者：
Lee YW;Lim SY;Lee JH;Lim JS;Kim M;Kwon S;Joo J;Kwak SH;Kim EO;Jung J;Kwon HS;Kim TB;Kim SH;Bae S
我们对接受两剂 BNT162b2 mRNA 疫苗的医护人员 (HCW) 自我报告的不良反应进行了一项基于移动设备的前瞻性调查。在完成两剂疫苗接种的 342 名医护人员中，265 名（77.5%）至少回复过一次调查。总体而言，第二剂后的不良反应发生率高于第一剂（89.1% vs. 80.1%，P = 0.006）。最常见的全身反应是肌肉疼痛（69.1%）、疲劳（65.7%）、头痛（48.7%）、寒战（44.2%）和发烧（32.1%），并且在第二剂疫苗后也更为常见。我们还注意到性别差异，即女性第二剂疫苗后不良反应的频率明显更高，而第一剂疫苗后未观察到这种情况。年龄较大组的不良反应发生率较低，且接种后 3 天内不良反应的发生率和严重程度均有所下降。
We conducted a prospective, mobile-based survey on the self-reported adverse reactions in healthcare workers (HCWs) who received both doses of the BNT162b2 mRNA vaccine. Of the 342 HCWs who completed the two-dose vaccination, 265 (77.5%) responded to the survey at least once. Overall, the rates of adverse reactions were higher after the second dose compared with the first dose (89.1% vs. 80.1%, P = 0.006). The most common systemic reactions were muscle ache (69.1%), fatigue (65.7%), headache (48.7%), chills (44.2%), and fever (32.1%), and were notably more common after the second dose vaccine as well. We also noted a sex difference in which the frequency of adverse reactions after the second dose of the vaccine was significantly higher in females, which was not observed after the first dose. The rates of adverse reactions were lower in older age groups, and the rates and severities of the adverse reactions decreased during the 3-day period following vaccination.
登录
查看更多内容
BNT162B2 mRNA COVID-19疫苗的安全性和功效。
DOI：
10.1056/nejmoa2034577
发表时间：
2020-12-31
期刊：
The New England journal of medicine
影响因子：
--
作者：
Polack FP;Thomas SJ;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Moreira ED;Zerbini C;Bailey R;Swanson KA;Roychoudhury S;Koury K;Li P;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Jansen KU;Gruber WC;C4591001 Clinical Trial Group
通讯作者：
C4591001 Clinical Trial Group
影响因子：
25.7
作者：
Rabinowich L;Grupper A;Baruch R;Ben-Yehoyada M;Halperin T;Turner D;Katchman E;Levi S;Houri I;Lubezky N;Shibolet O;Katchman H
通讯作者：
Katchman H
影响因子：
4.5
作者：
Bae S;Lee YW;Lim SY;Lee JH;Lim JS;Lee S;Park S;Kim SK;Lim YJ;Kim EO;Jung J;Kwon HS;Kim TB;Kim SH
通讯作者：
Kim SH
DOI：
10.1016/s1473-3099(21)00224-3
发表时间：
2021-07
期刊：
The Lancet. Infectious diseases
影响因子：
--
作者：
Menni C;Klaser K;May A;Polidori L;Capdevila J;Louca P;Sudre CH;Nguyen LH;Drew DA;Merino J;Hu C;Selvachandran S;Antonelli M;Murray B;Canas LS;Molteni E;Graham MS;Modat M;Joshi AD;Mangino M;Hammers A;Goodman AL;Chan AT;Wolf J;Steves CJ;Valdes AM;Ourselin S;Spector TD
通讯作者：
Spector TD
DOI：
10.1016/s1470-2045(21)00213-8
发表时间：
2021-06
期刊：
The Lancet. Oncology
影响因子：
--
作者：
Monin L;Laing AG;Muñoz-Ruiz M;McKenzie DR;Del Molino Del Barrio I;Alaguthurai T;Domingo-Vila C;Hayday TS;Graham C;Seow J;Abdul-Jawad S;Kamdar S;Harvey-Jones E;Graham R;Cooper J;Khan M;Vidler J;Kakkassery H;Sinha S;Davis R;Dupont L;Francos Quijorna I;O'Brien-Gore C;Lee PL;Eum J;Conde Poole M;Joseph M;Davies D;Wu Y;Swampillai A;North BV;Montes A;Harries M;Rigg A;Spicer J;Malim MH;Fields P;Patten P;Di Rosa F;Papa S;Tree T;Doores KJ;Hayday AC;Irshad S
通讯作者：
Irshad S